Cargando…

Detection of High-Risk Human Papillomavirus in Cervix Sample in an 11.3-year Follow-Up after Vaccination against HPV 16/18

Purpose the aim of this study was to evaluate the pattern of human papillomavirus (HPV) detection in an 11.3-year post-vaccination period in a cohort of adolescent and young women vaccinated or not against HPV 16/18. Methods a subset of 91 women from a single center participating in a randomized cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Teixeira, Cirbia Silva Campos, Teixeira, Julio Cesar, Oliveira, Eliane Regina Zambelli Mesquita, Machado, Helymar Costa, Zeferino, Luiz Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Revinter Publicações Ltda 2017
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316952/
https://www.ncbi.nlm.nih.gov/pubmed/28783858
http://dx.doi.org/10.1055/s-0037-1604133
_version_ 1785067818361815040
author Teixeira, Cirbia Silva Campos
Teixeira, Julio Cesar
Oliveira, Eliane Regina Zambelli Mesquita
Machado, Helymar Costa
Zeferino, Luiz Carlos
author_facet Teixeira, Cirbia Silva Campos
Teixeira, Julio Cesar
Oliveira, Eliane Regina Zambelli Mesquita
Machado, Helymar Costa
Zeferino, Luiz Carlos
author_sort Teixeira, Cirbia Silva Campos
collection PubMed
description Purpose the aim of this study was to evaluate the pattern of human papillomavirus (HPV) detection in an 11.3-year post-vaccination period in a cohort of adolescent and young women vaccinated or not against HPV 16/18. Methods a subset of 91 women from a single center participating in a randomized clinical trial (2001–2010, NCT00689741/00120848/00518336) with HPV 16/18 AS04-adjuvanted vaccine was evaluated. All women received three doses of the HPV vaccine (n = 48) or a placebo (n = 43), and cervical samples were collected at 6-month intervals. Only in this center, one additional evaluation was performed in 2012. Up to 1,492 cervical samples were tested for HPV-DNA and genotyped with polymerase chain reaction (PCR). The vaccine group characteristics were compared by Chi-square or Fisher exact or Mann-Whitney test. The high-risk (HR)-HPV 6-month-persistent infection rate was calculated. The cumulative infection by HPV group was evaluated by the Kaplan-Meier method and the log-rank test. Results the cumulative infection with any type of HPV in an 11.3-year period was 67% in the HPV vaccine group and 72% in the placebo group (p = 0.408). The longitudinal analysis showed an increase of 4% per year at risk for detection of HR-HPV (non-HPV 16/18) over time (p = 0.015), unrelated to vaccination. The cumulative infection with HPV 16/18 was 4% for the HPV vaccine group and 29% for the placebo group (p = 0.003). There were 43 episodes of HR-HPV 6-month persistent infection, unrelated to vaccination. Conclusions this study showed the maintenance of viral detection rate accumulating HR-HPV (non-HPV-16–18) positive tests during a long period post-vaccination, regardless of prior vaccination. This signalizes that the high number of HPV-positive tests may be maintained after vaccination.
format Online
Article
Text
id pubmed-10316952
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Thieme Revinter Publicações Ltda
record_format MEDLINE/PubMed
spelling pubmed-103169522023-07-27 Detection of High-Risk Human Papillomavirus in Cervix Sample in an 11.3-year Follow-Up after Vaccination against HPV 16/18 Teixeira, Cirbia Silva Campos Teixeira, Julio Cesar Oliveira, Eliane Regina Zambelli Mesquita Machado, Helymar Costa Zeferino, Luiz Carlos Rev Bras Ginecol Obstet Purpose the aim of this study was to evaluate the pattern of human papillomavirus (HPV) detection in an 11.3-year post-vaccination period in a cohort of adolescent and young women vaccinated or not against HPV 16/18. Methods a subset of 91 women from a single center participating in a randomized clinical trial (2001–2010, NCT00689741/00120848/00518336) with HPV 16/18 AS04-adjuvanted vaccine was evaluated. All women received three doses of the HPV vaccine (n = 48) or a placebo (n = 43), and cervical samples were collected at 6-month intervals. Only in this center, one additional evaluation was performed in 2012. Up to 1,492 cervical samples were tested for HPV-DNA and genotyped with polymerase chain reaction (PCR). The vaccine group characteristics were compared by Chi-square or Fisher exact or Mann-Whitney test. The high-risk (HR)-HPV 6-month-persistent infection rate was calculated. The cumulative infection by HPV group was evaluated by the Kaplan-Meier method and the log-rank test. Results the cumulative infection with any type of HPV in an 11.3-year period was 67% in the HPV vaccine group and 72% in the placebo group (p = 0.408). The longitudinal analysis showed an increase of 4% per year at risk for detection of HR-HPV (non-HPV 16/18) over time (p = 0.015), unrelated to vaccination. The cumulative infection with HPV 16/18 was 4% for the HPV vaccine group and 29% for the placebo group (p = 0.003). There were 43 episodes of HR-HPV 6-month persistent infection, unrelated to vaccination. Conclusions this study showed the maintenance of viral detection rate accumulating HR-HPV (non-HPV-16–18) positive tests during a long period post-vaccination, regardless of prior vaccination. This signalizes that the high number of HPV-positive tests may be maintained after vaccination. Thieme Revinter Publicações Ltda 2017-08 /pmc/articles/PMC10316952/ /pubmed/28783858 http://dx.doi.org/10.1055/s-0037-1604133 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Teixeira, Cirbia Silva Campos
Teixeira, Julio Cesar
Oliveira, Eliane Regina Zambelli Mesquita
Machado, Helymar Costa
Zeferino, Luiz Carlos
Detection of High-Risk Human Papillomavirus in Cervix Sample in an 11.3-year Follow-Up after Vaccination against HPV 16/18
title Detection of High-Risk Human Papillomavirus in Cervix Sample in an 11.3-year Follow-Up after Vaccination against HPV 16/18
title_full Detection of High-Risk Human Papillomavirus in Cervix Sample in an 11.3-year Follow-Up after Vaccination against HPV 16/18
title_fullStr Detection of High-Risk Human Papillomavirus in Cervix Sample in an 11.3-year Follow-Up after Vaccination against HPV 16/18
title_full_unstemmed Detection of High-Risk Human Papillomavirus in Cervix Sample in an 11.3-year Follow-Up after Vaccination against HPV 16/18
title_short Detection of High-Risk Human Papillomavirus in Cervix Sample in an 11.3-year Follow-Up after Vaccination against HPV 16/18
title_sort detection of high-risk human papillomavirus in cervix sample in an 11.3-year follow-up after vaccination against hpv 16/18
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316952/
https://www.ncbi.nlm.nih.gov/pubmed/28783858
http://dx.doi.org/10.1055/s-0037-1604133
work_keys_str_mv AT teixeiracirbiasilvacampos detectionofhighriskhumanpapillomavirusincervixsampleinan113yearfollowupaftervaccinationagainsthpv1618
AT teixeirajuliocesar detectionofhighriskhumanpapillomavirusincervixsampleinan113yearfollowupaftervaccinationagainsthpv1618
AT oliveiraelianereginazambellimesquita detectionofhighriskhumanpapillomavirusincervixsampleinan113yearfollowupaftervaccinationagainsthpv1618
AT machadohelymarcosta detectionofhighriskhumanpapillomavirusincervixsampleinan113yearfollowupaftervaccinationagainsthpv1618
AT zeferinoluizcarlos detectionofhighriskhumanpapillomavirusincervixsampleinan113yearfollowupaftervaccinationagainsthpv1618